HealthEdge Announces Exit of Scar Away to Perrigo

HealthEdge Announces Exit of Scar Away to Perrigo

TAMPA, FLORIDA – August 31, 2015 – HealthEdge Investment Partners, LLC (“HealthEdge”), a Tampa, FL healthcare focused investment firm, announced today that Fund I portfolio company Enaltus has sold ScarAway® (“ScarAway”) to Perrigo Company plc (“Perrigo”) (NYSE: PRGO; TASE). ScarAway is a leading U.S. OTC scar management brand and is expected to generate approximately $10 million in full, calendar year 2015 net sales or approximately $3 million for the remainder of 2015.

Perrigo Chairman, President and CEO Joseph C. Papa commented, "We are excited to add this marginenhancing asset to our already robust U.S. OTC portfolio and believe that by leveraging our unique distribution and customer network, Perrigo is well positioned to accelerate the growth of this brand. We remain committed to pursuing accretive transactions, such as this one, and to further the execution of our strategy as we continue to deliver superior value for our shareholders."

HealthEdge Managing Partner Phil Dingle said, “We are thrilled to exit our ScarAway brand to one of the leading consumer healthcare product businesses in the world. This marks the second significant sale of brand assets at Enaltus, our last remaining portfolio company in Fund I.”

Enaltus, headquartered in Suwannee, Georgia, specializes in unique skincare solutions with direct operations in the U.S. and global distribution partnerships.

About HealthEdge HealthEdge Investment Partners, LLC is an operating‐oriented private equity firm founded in 2005 that focuses exclusively on the healthcare industry. HealthEdge seeks to achieve superior returns by investing in businesses that benefit from the knowledge, experience, and network of relationships of its partners. HealthEdge’s partners have more than 100 years of combined operating experience in healthcare as CEOs and investors. For more information on HealthEdge, please visit

For more information, please contact Phil Dingle at HealthEdge Investment Partners at (813) 490-7101.